Interstitial Lung Diseases Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's "Interstitial Lung Diseases Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Diseases pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Interstitial Lung Diseases pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Interstitial Lung Diseases Pipeline. Dive into DelveInsight's comprehensive report today! @ Interstitial Lung Diseases Pipeline Outlook [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Interstitial Lung Diseases Pipeline Report

* In May 2025, aTyr Pharma Inc. announced a study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1 of 2 active (experimental) dose arms or placebo, administered every 4 weeks up to and including Week 20. Part B is an optional open-label extension to Part A in which participants can receive 450 mg efzofitimod every 4 weeks for 6 doses.
* In May 2025, Boehringer Ingelheim conducted a study is open to children and adolescents with interstitial lung disease (ILD) that causes lung fibrosis. This is a study for people who took part in a previous study called InPedILD (study 1199-0337) and for people who are between 6 and 17 years old (in France, between 12 and 17 years old) and have fibrosing ILD.
* In May 2025, Rein Therapeutics organized a study that includes a 28-day Screening Period, a 24-week Treatment Period, and 4-week Follow-up Period. Safety and tolerability will be evaluated with the following assessments: physical examination; collection of vital sign data (heart rate, blood pressure, respiratory rate and peripheral oxygen saturation [SpO2] via pulse oximetry); heart data collected by 12-lead electrocardiogram; and collection of blood samples for safety laboratory tests.
* In May 2025, Kadmon Corporation LLC announced a Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized female subjects with Idiopathic Interstitial Lung Diseases (IPF).
* In May 2025, Bristol-Myers Squibb announced a phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Interstitial Lung Diseases.
* DelveInsight's Interstitial Lung Diseases Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Interstitial Lung Diseases treatment.
* The leading Interstitial Lung Diseases Companies such as Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.
* Promising Interstitial Lung Diseases Pipeline Therapies such as Dotarem, efzofitimod 450 mg, Fentanyl Citrate, Belimumab, Nintedanib (Ofev Registered ), Anlotinib, Pirfenidone, BI 1015550, Bosentan, Mycophenolate mofetil, Cyclophosphamide and others.

Stay ahead with the most recent pipeline outlook for Interstitial Lung Diseases. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Interstitial Lung Diseases Treatment Drugs [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Interstitial Lung Diseases Emerging Drugs Profile

* DWN12088: Daewoong Pharmaceutical

DWN12088 is an investigational therapy for idiopathic Interstitial Lung Diseases (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body's ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein's sequence. The FDA designated it as an orphan drug for idiopathic Interstitial Lung Diseases (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.

* LYT-100: PureTech

LYT-100 is PureTech's most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022.

* BMS-986278: Bristol-Myers Squibb

BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic Interstitial Lung Diseases. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and -arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation.

The Interstitial Lung Diseases Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Diseases with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Diseases Treatment.
* Interstitial Lung Diseases Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Interstitial Lung Diseases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Diseases market

Explore groundbreaking therapies and clinical trials in the Interstitial Lung Diseases Pipeline. Access DelveInsight's detailed report now! @ New Interstitial Lung Diseases Drugs [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Interstitial Lung Diseases Companies

Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous

Interstitial Lung Diseases Products have been categorized under various Molecule types such as

* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy

Unveil the future of Interstitial Lung Diseases Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Interstitial Lung Diseases Market Drivers and Barriers [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Interstitial Lung Diseases Pipeline Report

* Coverage- Global
* Interstitial Lung Diseases Companies- Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.
* Interstitial Lung Diseases Pipeline Therapies- Dotarem, efzofitimod 450 mg, Fentanyl Citrate, Belimumab, Nintedanib (Ofev Registered ), Anlotinib, Pirfenidone, BI 1015550, Bosentan, Mycophenolate mofetil, Cyclophosphamide and others.
* Interstitial Lung Diseases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Interstitial Lung Diseases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Interstitial Lung Diseases Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Interstitial Lung Diseases Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Interstitial Lung Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Interstitial Lung Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* RO-0220912: Roche
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Daratumumab: Janssen Biotech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* BGB 16673: BeiGene
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug name: Company name
* Inactive Products
* Interstitial Lung Disease Key Companies
* Interstitial Lung Disease Key Products
* Interstitial Lung Disease- Unmet Needs
* Interstitial Lung Disease- Market Drivers and Barriers
* Interstitial Lung Disease- Future Perspectives and Conclusion
* Interstitial Lung Disease Analyst Views
* Interstitial Lung Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=interstitial-lung-diseases-pipeline-appears-robust-with-120-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.